Citi Issuer Services, acting through Citibank N.A., has been appointed by Vicore Pharma Holding AB to act as the depositary bank for its sponsored Level 2 American Depositary Receipt (ADR) program. This appointment facilitates Vicore Pharma's access to global capital markets through Citi's industry-leading ADR solutions and extensive global network.

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's ADRs trade on the Nasdaq Capital Market under the symbol "VCRE". Each American Depositary Share (ADS) represents ten ordinary shares of the company. Vicore Pharma's underlying ordinary shares are listed and traded on the Nasdaq Stockholm Stock Exchange under the symbol "VICO".

Dirk Jones, Head of Issuer Services at Citi, emphasized the bank's commitment to supporting Vicore Pharma. "We are committed to supporting Vicore Pharma with high quality services through our industry-leading ADR solutions. Our deep capital markets expertise and extensive global network enable us to facilitate seamless access to global capital markets for issuers like Vicore Pharma," said Jones.

Citi Issuer Services is a leading provider of depositary receipt services, with programs in over 65 markets spanning equity and fixed-income products. The unit leverages Citi's global network to provide cross-border capital market access to issuers, intermediaries, and investors.

Key Details of Vicore Pharma's ADR Program